tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2016-3-54-59tumors-261Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL REPORTSРецептор эпидермального фактора роста как мишень молекулярно-направленной терапии у непредлеченных пациентов с немелкоклеточным раком легкогоEpidermal growth factor receptor as target of moleculartargeted therapy in patients with primary non-small cell lung cancerСАКАЕВАД. Д.SAKAEVAD. D.

д. м.н., профессор, заместитель главного врача

MD, RhD, DSc, professor, deputy chief doctor

d_sakaeva@mail.ruГОРДИЕВМ. Г.GORDIEVM. G.

заведующий молекулярно-диагностической лабораторией 

chief of molecular-diagnostic laboratory

marat7925@gmail.comГБУЗ РКОД МЗ РБ г. УфаРоссияSBHI Republican clinical oncology dispensary of MoH of Bashkortostan Republic in UfaRussian FederationГБУЗ РКОД МЗ РТ г. КазаньРоссияSAHI, Republican clinical oncology dispensary of MoH of Tatarstan Republic, KazanRussian Federation201616102016035459Copyright © САКАЕВА Д.Д., ГОРДИЕВ М.Г., 20162016САКАЕВА Д.Д., ГОРДИЕВ М.Г.SAKAEVA D.D., GORDIEV M.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/261

Рецептор эпидермального фактора роста (EGFR) – один из наиболее важных и наиболее изученных сигнальных путей, регулирующий рост, выживаемость, пролиферативную активность и дифференцировку клеток у млекопитающих [1]. В тоже время EGFR и семейство белков – эпидермальных факторов роста, играют центральную роль в патогенезе и прогрессии различных видов опухолей [2]. В 80-х годах прошлого века была выдвинута гипотеза о том, что данный сигнальный путь может стать мишенью для лекарственной терапии [1]. В настоящее время существует 3 поколения ингибиторов тирозинкиназ (ИТК) EGFR. Препараты данного класса активно используются в клинической практике для лечения больных распространенным НМРЛ с наличием мутации гена EGFR. Исследования этих препаратов продолжаются. В данном обзоре освещены возможности использования ИТК в 1-й линии терапии распространенного НМРЛ, а также в адъювантном режиме.

Epidermal Grows factor receptor (EGFR) is one of the most significant and studied signaling pathway, regulating growth, survival, proliferation and differentiation of mamllian cells. At the same time EGFR and its protein family play a central role in pathogenesis and progression of different type of tumors. In the 80-s, it was proposed that this signaling pathway could be the target for the therapy. Today there are 3 generations of tyrosine kinase inhibitors (TKIs). This drug class is actively used in clinical practice for therapy of patients with EGFR mutation positive advanced non small cell lung cancer (NSCLC). Investigation of TKIs is continuing. In this review, the options of TKI use in the adjuvant setting and the 1st line treatment of advanced NSCLC are highlighted.

EGFR мутацияИТКНМРЛEGFR mutationTKIsNSCLCReferencesD.S. Salomon, R. Brandt, F. Ciardiello, N. Normanno «Epidermal growth factor-related peptides and their receptors in human malignancies», Crit. Rev. Oncol. Hematol., 19 (1995), pp. 183–232.D.S. Salomon, R. Brandt, F. Ciardiello, N. Normanno «Epidermal growth factor-related peptides and their receptors in human malignancies», Crit. Rev. Oncol. Hematol., 19 (1995), pp. 183–232.Oda K., Matsuoka Y., Funahashi A., Kitano H. (2005). «A comprehensive pathway map of epidermal growth factor receptor signaling». Mol. Syst. Biol. 1 (1): 2005.0010.Oda K., Matsuoka Y., Funahashi A., Kitano H. (2005). «A comprehensive pathway map of epidermal growth factor receptor signaling». Mol. Syst. Biol. 1 (1): 2005.0010.Gazdar A. F. et al. «Inhibition of EGFR Signaling: All Mutations Are Not Created Equal Trends» Mol Med 2004; 10: 481–486.Gazdar A. F. et al. «Inhibition of EGFR Signaling: All Mutations Are Not Created Equal Trends» Mol Med 2004; 10: 481–486.Sharma S. et al. «Epidermal growth factor receptor mutations in lung cancer». Nat Rev Cancer 2007; 7:169–81.Sharma S. et al. «Epidermal growth factor receptor mutations in lung cancer». Nat Rev Cancer 2007; 7:169–81.В.М. Моисеенко, С. А. Проценко, И. И. Семенов. Современная Онкология № 1, том 12, 2010, 60–66. V. M. Moiseenko, S. A. Protsenko, I. I. Semenov, Sovremennaya Onkologiya №1, vol 12, 2010,60–66.В.М. Моисеенко, С. А. Проценко, И. И. Семенов. Современная Онкология № 1, том 12, 2010, 60–66. V. M. Moiseenko, S. A. Protsenko, I. I. Semenov, Sovremennaya Onkologiya №1, vol 12, 2010,60–66.Практические рекомендации по лечению злокачественных опухолей. Портал Российского общества клинической онкологии rosoncoweb.ru [Электронный ресурс], 06.06.16, URL: http://www.rosoncoweb.ru/standarts/RUSSCO/01.pdf Prakticheskie rekommendacii po lecheniyu zlokachestvennyh opukholei. Portal Rossiiskogo obschestva klinicheskoy onkologii rosoncoweb.ru. [Electronic resource], 06.06.16, URL: http://www.rosoncoweb.ru/standarts/RUSSCO/01.pdfПрактические рекомендации по лечению злокачественных опухолей. Портал Российского общества клинической онкологии rosoncoweb.ru [Электронный ресурс], 06.06.16, URL: http://www.rosoncoweb.ru/standarts/RUSSCO/01.pdf Prakticheskie rekommendacii po lecheniyu zlokachestvennyh opukholei. Portal Rossiiskogo obschestva klinicheskoy onkologii rosoncoweb.ru. [Electronic resource], 06.06.16, URL: http://www.rosoncoweb.ru/standarts/RUSSCO/01.pdfM. Reck, S. Popat, N. Reinmuth, D. De Ruysscher, K. M. Kerr and S. Peters, «Metastatic non-small-cell lung cancer (NSCLC): SMO Clinical Practice Guidelines for diagnosis, treatment and follow-up». Ann Oncol (2014) 25 (suppl 3): iii27-iii39.M. Reck, S. Popat, N. Reinmuth, D. De Ruysscher, K. M. Kerr and S. Peters, «Metastatic non-small-cell lung cancer (NSCLC): SMO Clinical Practice Guidelines for diagnosis, treatment and follow-up». Ann Oncol (2014) 25 (suppl 3): iii27-iii39.Masters et al. «Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update». JCO August 31, 2015, 1–30.Masters et al. «Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update». JCO August 31, 2015, 1–30.NCCN Guidelines. Портал национальной всеобщей онкологической сети nccn.org. [Электронный ресурс], 06.06.16, URL: http://www.nccn.org/professionals/physician_ gls/pdf/nscl.pdf NCCN Guidelines. Portal nacional’noj vseobshhej onkologicheskoj seti nccn.org. [Jelektronnyj resurs], 06.06.16, URL: http://www.nccn.org/professionals/physician_gls/pdf/ nscl.pdfNCCN Guidelines. Портал национальной всеобщей онкологической сети nccn.org. [Электронный ресурс], 06.06.16, URL: http://www.nccn.org/professionals/physician_ gls/pdf/nscl.pdf NCCN Guidelines. Portal nacional’noj vseobshhej onkologicheskoj seti nccn.org. [Jelektronnyj resurs], 06.06.16, URL: http://www.nccn.org/professionals/physician_gls/pdf/ nscl.pdfTony S. Mok, Yi-Long Wu, Sumitra Thongprasert, Chih- Hsin Yang, Da-Tong Chu, Nagahiro Saijo, et al. «Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma», N Engl J Med 2009; 361:947–957.Tony S. Mok, Yi-Long Wu, Sumitra Thongprasert, Chih- Hsin Yang, Da-Tong Chu, Nagahiro Saijo, et al. «Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma», N Engl J Med 2009; 361:947–957.Han J. Y., Park K., Kim S. W. et al. First-signal: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012; 30:1122–8.Han J. Y., Park K., Kim S. W. et al. First-signal: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012; 30:1122–8.Maemondo M., Inoue A., Kobayashi K. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362:2380–8.Maemondo M., Inoue A., Kobayashi K. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362:2380–8.Mitsudomi T., Morita S., Yatabe Y. et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WTJOG 3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11:121–8.Mitsudomi T., Morita S., Yatabe Y. et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WTJOG 3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010; 11:121–8.Zhou C., Wu Y. L., Chen G. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG‑0802): a multicentre, open-label, randomized, phase 3 study. Lancet Oncol. 2011; 12:735–42.Zhou C., Wu Y. L., Chen G. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG‑0802): a multicentre, open-label, randomized, phase 3 study. Lancet Oncol. 2011; 12:735–42.Rosell R., Carcereny E., Gervais R. et al. Erlotinib versus standard chemotherapy as first- line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2012; 13:239–46.Rosell R., Carcereny E., Gervais R. et al. Erlotinib versus standard chemotherapy as first- line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2012; 13:239–46.Cesare Gridelli, Fortunato Ciardiello, Ciro Gallo, Ronald Feld, Charles Butts et al. First- Line Erlotinib Followedby Second-Line CisplatinGemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial J Clinical Oncol. Vol 30 Num 24 2012:3002–3011.Cesare Gridelli, Fortunato Ciardiello, Ciro Gallo, Ronald Feld, Charles Butts et al. First- Line Erlotinib Followedby Second-Line CisplatinGemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial J Clinical Oncol. Vol 30 Num 24 2012:3002–3011.Lecia V. Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth O’Byrne et al. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. J Clin Oncol 2013; Vol 31 Num 27:3327–3334;Lecia V. Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, Kenneth O’Byrne et al. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations. J Clin Oncol 2013; Vol 31 Num 27:3327–3334;Wu Y.L., Zhou C., Hu C.P. et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX–Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15: 213–222.Wu Y.L., Zhou C., Hu C.P. et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX–Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014; 15: 213–222.Сервис Национального Института Здоровья США// Портал ClinicalTrials.gov [Электронный ресурс], 20.10.15. URL: https://clinicaltrials.gov/ct2/results? term=chemotherapy+and+ TKI+NSCLC&Search=Search Servis Nacional’nogo Instituta Zdorov’ja SShA// Portal ClinicalTrials.gov [Jelektronnyj resurs], 20.10.15. URL: https://clinicaltrials.gov/ct2/results?term= chemotherapy+and+ TKI+NSCLC&Search=Search 20. Wu Y. L., Lee J. S., Thongprasert S., Yu C. J., Zhang L., Ladrera G. et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT‑2): a randomised, double-blind trial. Lancet Oncol. 2013 Jul; 14(8):777–86.Сервис Национального Института Здоровья США// Портал ClinicalTrials.gov [Электронный ресурс], 20.10.15. URL: https://clinicaltrials.gov/ct2/results? term=chemotherapy+and+ TKI+NSCLC&Search=Search Servis Nacional’nogo Instituta Zdorov’ja SShA// Portal ClinicalTrials.gov [Jelektronnyj resurs], 20.10.15. URL: https://clinicaltrials.gov/ct2/results?term= chemotherapy+and+ TKI+NSCLC&Search=Search 20. Wu Y. L., Lee J. S., Thongprasert S., Yu C. J., Zhang L., Ladrera G. et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT‑2): a randomised, double-blind trial. Lancet Oncol. 2013 Jul; 14(8):777–86.Kanda S. et al. Phase II study of gefitinib and inserted cisplatin plus docetaxel as a first-line treatment for advanced nonsmall cell lung cancer haboring an epidermal growth factor receptor activating mutation. ASCO 2013, abs 8064 J Clin Oncol 31, 2013 (suppl; abstr 8064).Kanda S. et al. Phase II study of gefitinib and inserted cisplatin plus docetaxel as a first-line treatment for advanced nonsmall cell lung cancer haboring an epidermal growth factor receptor activating mutation. ASCO 2013, abs 8064 J Clin Oncol 31, 2013 (suppl; abstr 8064).S. Sugawara, S. Oizumi, K. Minato et al. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902Ann Oncol (2015) 26 (5): 888–894.S. Sugawara, S. Oizumi, K. Minato et al. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902Ann Oncol (2015) 26 (5): 888–894.O.Ishimoto, S. Oizumi, K. Minato et al. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ005/ TCOG0902. Annals of Oncology 25 (Supplement 4): iv426– iv470, 2014.O.Ishimoto, S. Oizumi, K. Minato et al. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ005/ TCOG0902. Annals of Oncology 25 (Supplement 4): iv426– iv470, 2014.Ying Cheng, Haruyasu Murakami, Pan-Chyr Yang, Jianxing He, Kazuhiko Nakagawa et al. Randomized Trial of Gefitinib with and without Pemetrexed as First-Line Therapy in East- Asian Patients with Advanced NS NSCLC with EGFR Mutations. Journal of Thoracic Oncology, Vol 10, Sup 2, 2015, S206 (ORAL 17.02).Ying Cheng, Haruyasu Murakami, Pan-Chyr Yang, Jianxing He, Kazuhiko Nakagawa et al. Randomized Trial of Gefitinib with and without Pemetrexed as First-Line Therapy in East- Asian Patients with Advanced NS NSCLC with EGFR Mutations. Journal of Thoracic Oncology, Vol 10, Sup 2, 2015, S206 (ORAL 17.02).D’Angelo S.P. et al. Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers J Thorac Oncol. 2012; 7: 1815–1822.D’Angelo S.P. et al. Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers J Thorac Oncol. 2012; 7: 1815–1822.Karen Kelly, Nasser K. Altorki, Wilfried E. E. Eberhardt, Mary E. R. O’Brien et al. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. V. 33, Num. 34, 2015: 1–8Karen Kelly, Nasser K. Altorki, Wilfried E. E. Eberhardt, Mary E. R. O’Brien et al. Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. V. 33, Num. 34, 2015: 1–8Сервис Национального Института Здоровья США// Портал ClinicalTrials.gov [Электронный ресурс], 07.06.16. URL: https://clinicaltrials.gov/ct2/show/ NCT02511106? term=ADAURA&rank=1 Servis Nacional’nogo Instituta Zdorov’ja SShA// Portal ClinicalTrials.gov [Jelektronnyj resurs], 07.06.16. URL: https://clinicaltrials.gov/ct2/show/ NCT02511106?term=ADAURA&rank=1Сервис Национального Института Здоровья США// Портал ClinicalTrials.gov [Электронный ресурс], 07.06.16. URL: https://clinicaltrials.gov/ct2/show/ NCT02511106? term=ADAURA&rank=1 Servis Nacional’nogo Instituta Zdorov’ja SShA// Portal ClinicalTrials.gov [Jelektronnyj resurs], 07.06.16. URL: https://clinicaltrials.gov/ct2/show/ NCT02511106?term=ADAURA&rank=1Pasi A. J nne, James Chih-Hsin Yang, Dong-Wan Kim, David Planchard, Yuichiro Ohe, Suresh S. et al. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer, N Engl J Med 2015; 372:1689–1699.Pasi A. J nne, James Chih-Hsin Yang, Dong-Wan Kim, David Planchard, Yuichiro Ohe, Suresh S. et al. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer, N Engl J Med 2015; 372:1689–1699.Catherine A. Eberlein, Daniel Stetson, Aleksandra A. Markovets, et al. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. Cancer Res; 75(12) June 15, 2015, 2489–2500.Catherine A. Eberlein, Daniel Stetson, Aleksandra A. Markovets, et al. Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models. Cancer Res; 75(12) June 15, 2015, 2489–2500.

The authors declare that there are no conflicts of interest present.